Emerg Infect Dis by Petridou, Christina et al.
1598 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 25, No. 8, August 2019
RESEARCH LETTERS
References
  1. Shayan S, Bokaean M, Shahrivar MR, Chinikar S. Crimean- 
Congo hemorrhagic fever. Lab Med. 2015;46:180–9.  
http://dx.doi.org/10.1309/LMN1P2FRZ7BKZSCO
  2. Mertens M, Schmidt K, Ozkul A, Groschup MH. The impact  
of Crimean-Congo hemorrhagic fever virus on public health.  
Antiviral Res. 2013;98:248–60. http://dx.doi.org/10.1016/ 
j.antiviral.2013.02.007
  3. Mustafa ML, Ayazi E, Mohareb E, Yingst S, Zayed A, Rossi CA, 
et al. Crimean-Congo hemorrhagic fever, Afghanistan, 2009. 
Emerg Infect Dis. 2011;17:1940–1. http://dx.doi.org/10.3201/
eid1710.110061
  4. Niazi A-u-R. Clinical epidemiology of Crimean-Congo  
hemorrhagic fever in west region of Afghanistan. Herat  
(Afghanistan): Herat University Press; 2017.
  5. World Health Organization. Communicable disease profile. 
Afghanistan and neighboring countries. January 2002 [cited 2012 
Apr 17]. https://www.who.int/diseasecontrol_emergencies/toolkits/
Afghanistan_profile.pdf
  6. Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM. The frequency 
and clinical significance of thrombocytopenia complicating  
critical illness: a systematic review. Chest. 2011;139:271–8.  
http://dx.doi.org/10.1378/chest.10-2243
  7. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, 
Harvey S. The clinical pathology of Crimean-Congo  
hemorrhagic fever. Rev Infect Dis. 1989;11(Suppl 4):S794–800. 
http://dx.doi.org/10.1093/clinids/11.Supplement_4.S794
  8. Tezer H, Polat M. Diagnosis of Crimean-Congo hemorrhagic fever. 
Expert Rev Anti Infect Ther. 2015;13:555–66. http://dx.doi.org/ 
10.1586/14787210.2015.1021782
  9. Bastug A, Kayaaslan B, Kazancioglu S, Aslaner H, But A,  
Akinci E, et al. Crimean-Congo hemorrhagic fever: prognostic  
factors and the association of leukocyte counts with mortality.  
Jpn J Infect Dis. 2016;69:51–5. http://dx.doi.org/10.7883/ 
yoken.JJID.2014.566
10. Chamberlain J, Atkinson B, Logue CH, Latham J, Newman ENC, 
Hewson R. Genome sequence of ex-Afghanistan Crimean-Congo 
hemorrhagic fever virus SCT strain, from an imported United  
Kingdom case in October 2012. Genome Announc. 
2013;1:e00161–13. http://dx.doi.org/10.1128/genomeA.00161-13
Address for correspondence: David T. Williams, CSIRO, Australian 
Animal Health Laboratory, 5 Portarlington Rd, Geelong, VIC 3220, 
Australia; email: d.williams@csiro.au
Prolonged Zika Virus RNA  
Detection in Semen of  
Immunosuppressed Patient
Christina Petridou, David Bonsall,  
Aleem Ahmed, Mark Roberts, Carolyn Bell, 
Mariateresa de Cesare, Rory Bowden,  
Victoria Graham, Daniel Bailey,  
Andrew Simpson, Emma Aarons
Author affiliations: Rare and Imported Pathogens Laboratory,  
Public Health England Porton, Salisbury, UK (C. Petridou,  
V. Graham, D. Bailey, A. Simpson, E. Aarons); University of  
Oxford, Oxford, UK (D. Bonsall, M. de Cesare, R. Bowden); 
Leicester Royal Infirmary, Leicester, UK (A. Ahmed);  
Worcestershire Royal Hospital, Worcester, UK (M. Roberts);  
South Warwickshire National Health System Foundation Trust, 
Warwick, UK (C. Bell)
DOI: https://doi.org/10.3201/eid2508.181543
Zika virus RNA has been detected in semen samples col-
lected <370 days after symptom onset. We report unusual 
persistence of Zika virus RNA in semen, confirmed by se-
quencing at 515 days after symptom onset and detectable 
for >900 days, in a patient with immunosuppression.
Detection of Zika virus RNA in semen was described previously in an immunocompetent man 370 days after 
symptom onset; envelope and precursor of M protein gene 
sequencing indicated high genetic stability in semen 3–4 
months after symptom onset (1). We report detection of Zika 
virus RNA in semen over a longer period in a 43-year-old 
immunosuppressed man in the United Kingdom.
The patient has multicentric reticulohistiocytosis 
(MRH), a rare rheumatologic condition, which was di-
agnosed in 2015. When MRH was diagnosed, the pa-
tient had multiple pruritic, firm papules and nodules on 
his face and neck. He also had lesions with a character-
istic coral bead appearance at periungal sites. In addi-
tion, he had severe joint pain and stiffness affecting his 
hands and knees and drenching sweats. His MRH diag-
nosis was confirmed by testing of a punch biopsy of a 
lesion. He was HIV negative, and his immunoglobulin 
levels and immunoglobulin electrophoresis results were 
normal. He was initially treated with topical steroids 
and antihistamines, but he only had limited relief. He 
was prescribed oral steroids and required high doses to 
control his symptoms. Clinicians added methotrexate 
and hydroxychloroquine to his medications as steroid-
sparing agents and to reduce the chance his MRH would 
progress to erosive disease.
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In April 2016, seven months after starting his dis-
ease-modifying antirheumatic drugs, the patient experi-
enced fever and a new widespread maculopapular rash. 
He had returned to the United Kingdom from Brazil 7 
days before. We detected Zika virus RNA in plasma tak-
en 1 day after symptom onset by using real-time reverse 
transcription PCR methods described by Pyke et al. (2), 
with modifications (Appendix, http://wwwnc.cdc.gov/
EID/article/25/8/18-1543-App1.pdf). We did not detect 
Zika virus nonstructural protein 1–specific antibodies 
by ELISA (EUROIMMUN, https://www.euroimmun.
com) in initial samples, but we noted seroconversion on 
day 13 (Appendix Figure). After diagnosing Zika virus 
infection, clinicians stopped the patient’s methotrexate 
and hydroxychloroquine, but he remained on predniso-
lone to prevent a flare-up of his MRH (Appendix Fig-
ure). The patient’s clinical course of Zika virus infection 
was unremarkable.
A previous study reported that Zika virus RNA 
was detected in several semen samples taken within 6 
months of symptom onset (3). We tested subsequent 
semen samples from this patient and found Zika virus 
RNA persisted at a viral load sufficient for sequencing 
515 days after symptom onset (Table; Appendix Figure). 
To date, Zika virus RNA remains detectable in further 
semen samples, although at higher cycle threshold val-
ues (Table). The patient remains asymptomatic for Zika 
virus infection despite persistent detection of Zika virus 
RNA in his semen.
We attempted viral culture on multiple semen samples, 
as previously described (3), but were unsuccessful (Table). 
We constructed sequencing libraries from total seminal plas-
ma-extracted RNA enriched by using a panel of oligonucle-
otide probes, 120 nt in length, designed to capture all known 
Asian Zika virus strains, according to previously described 
methods (4). We prepared libraries for previously collected 
semen samples from before day 326 and sequenced these us-
ing MinION (Oxford Nanopore Technologies, https://nano-
poretech.com). We did the same for the day 515 sample and 
sequenced it using MiSeq (Illumina, https://www.illumina.
com). We used double indexing to prevent cross-contamina-
tion and index misassignment errors. 
We also prepared 90 plasma samples from patients in-
fected with hepatitis C, collected for a separate study, in 
parallel with the day 515 sample. We did this to exclude the 
possibility of cross-contamination from our patient’s previ-
ous samples, particularly the day 13 sample, which were 
shipped, prepared, and sequenced 6 months earlier. We did 
not detect Zika virus in any of the hepatitis C samples. We 
found no evidence of cross-contamination with Zika virus 
sequences during processing that could explain the near-
whole genomes detected in the day 515 sample. Consensus 
sequences were consistent with all samples having come 
from the same patient with only 2 mutations, 1 synonymous 
change at codon 2921 and a K3272E substitution, acquired 
during the 502 days between the first and last samples se-
quenced (Table). We deposited sequence data in GenBank 
(accession nos. MH763832–3).
 
Table. Serial Zika virus genome sequence and culture results from semen of a patient with immunosuppression, United Kingdom* 
Sample 
no. 
Days after 
symptom onset 
RT-PCR Ct 
value† 
Sequence coverage, 
%‡ 
Average 
read depth 
Sequencing 
platform§ 
Mutations 
detected 
Culture result 
1 13 19 99.9 (min depth 2), 
88.4 (min depth 40) 
386.9 MinION Reference Frozen sample: 
unsuccessful 
2 46 26 ND  NA NA Fresh sample: 
unsuccessful 
3 167 Subthreshold ND  NA NA ND 
4 194 No RNA 
detected¶ 
ND  NA NA ND 
5 241 31 Unsuccessful  NA NA ND 
6 257 34 44 (min depth 2), 0 
(min depth 40) 
3.3 MinION None Frozen sample: 
unsuccessful 
7 278 No RNA 
detected¶ 
ND  NA NA ND 
8 326 26 76 (min depth 2), 6 
(min depth 40) 
13.2 MinION None Fresh sample: 
unsuccessful 
9 396 29 ND  NA NA ND 
10 515 24 98.1 (min depth 5) 33.3 MiSeq K3272E, 
Syn2921 
Fresh sample: 
unsuccessful 
11 687 39 ND  NA NA ND 
12 941 32 ND  NA NA ND 
*Ct, cycle threshold; min, minimum; NA, not applicable; ND, not done; RT-PCR, reverse transcription PCR. 
†Before PCR, nucleic acid was extracted from samples 1–7 using the EZ1 Virus Mini Kit (QIAGEN, https://www.qiagen.com). Samples 8–12 were 
extracted using the MagNA Pure 96 DNA and Viral NA Small Volume Kit (LifeScience-Roche Diagnostics Corporation, https://lifescience.roche.com). Ct 
values <40 with acceptable amplification curves are interpreted as positive, but results for samples with Ct values >35 are confirmed by reextraction and 
repeat PCR in triplicate, where possible. 
‡Conservative read-depth thresholds were selected for comparative analyses of the day 13 (sample 1) and day 515 (sample 10) consensus genomes. 
§MinION (Oxford Nanopore Technologies, https://nanoporetech.com); MiSeq (Illumina, https://www.illumina.com). 
¶Confirmed on reextraction and repeat PCR testing. 
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Counotte et al. systematically reviewed all available 
evidence on the risk for sexual transmission of Zika virus 
(5). Data from case reports, case series, cohort studies, in 
vitro work, and animal studies indicate that the infectious 
period for sexual transmission of Zika virus is consider-
ably shorter than the period during which viral RNA can 
be detected in semen. As a result, the World Health Or-
ganization now recommends male travelers with poten-
tial Zika virus exposure delay conception for >3 months 
rather than >6 months (6). 
In our case, Zika virus RNA might have persisted 
in semen because of failed immune clearance second-
ary to the patient’s MRH or his immunosuppressive drug 
treatment. However, when advising returning male trav-
elers in couples planning pregnancy, clinicians should 
be aware that Zika virus RNA shedding in semen might 
be intermittent and persist for longer in patients with im-
munosuppression.
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Cutavirus was previously found in cutaneous melanoma. 
We detected cutavirus DNA in only 2/185 melanoma bi-
opsies and in 0/52 melanoma metastases from patients in 
Germany. Viral DNA was localized in the upper epidermal 
layers. Swab specimens from healthy skin were cutavirus 
positive for 3.8% (9/237) of immunocompetent and 17.1% 
(35/205) of HIV-positive men.
Cutavirus, a novel human protoparvovirus with lin-ear single-stranded DNA, has been detected in fecal 
samples from children with diarrhea and in cutaneous T-
cell lymphomas (CTCL) (1,2). Recently, Mollerup et al. 
reported the identification of cutavirus in 1 of 10 cutane-
ous malignant melanomas using viral enrichment methods 
with high-throughput sequencing and real-time PCR (3). 
This discovery raised questions concerning tropism and 
pathogenicity of cutavirus in human skin. We performed 
a retrospective study to determine cutavirus DNA preva-
lence and viral load in a large collection of formalin-fixed 
paraffin-embedded tissue biopsy specimens of malignant 
melanomas and in forehead swabs of healthy skin of im-
munocompetent and HIV-positive persons in Germany.
We used 185 cutaneous malignant melanoma biopsy 
specimens from 179 patients and 52 melanoma metastases 
from 42 patients from Germany for analyses with cutavi-
rus real-time PCR (Appendix, http://wwwnc.cdc.gov/EID/
article/25/8/19-0096-App1.pdf). We detected cutavirus 
DNA only in 2 nodular malignant melanomas, located on 
the abdomen of a 64-year-old man (MM-A) and on the 
cheek of an 85-year-old woman (MM-B). Viral DNA loads 
in these biopsies were 0.3 (MM-A) and 2.8 (MM-B) cuta-
virus DNA copies per β-globin gene copy. None of the 52 
analyzed metastases carried cutavirus DNA (Table). The 
cutavirus PCR results of the 2 melanomas could be con-
firmed by sequencing and by in situ hybridization. In both 
melanomas, the cutavirus DNA–specific signals could be 
